Search Results

You are looking at 1 - 10 of 220 items for :

Clear All
Full access

Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff and Hannah M. Linden

Background Changes in estrogen receptor (ER) expression over the course of therapy may affect response to endocrine therapy. However, measuring temporal changes in ER expression requires serial biopsies, which are impractical and poorly

Full access

D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt and Antonio C. Wolff

. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy . Cancer 1980 ; 46 ( 12 Suppl ): 2838 – 2841 . 4 Osborne CK Yochmowitz MG Knight WA III McGuire WL . The value of estrogen and

Full access

Rondi M. Kauffmann, Leanne Goldstein, Emily Marcinkowski, George Somlo, Yuan Yuan, Philip H.G. Ituarte, Laura Kruper, Leslie Taylor and Courtney Vito

with DCIS treated in California, and to identify factors associated with recommending anti-e in patients with estrogen receptor–positive (ER+) DCIS. Methods This study was approved by the California Review Board (CPHS), the CCR, and by the

Full access

Gayathri Nagaraj and Cynthia X. Ma

. Describe the ideal treatment with adjuvant chemotherapy for patients with estrogen receptor (ER)-positive HER2-negative lymph node-negative breast cancer. Case Report A 67-year-old otherwise healthy postmenopausal woman presented for adjuvant

Full access

Rowan T. Chlebowski, Aaron K. Aragaki and Garnet L. Anderson

Menopausal hormone therapy was introduced into clinical practice in the United States more than 60 years ago with the FDA approval of conjugated equine estrogen in the early 1940s. 1 When an increased risk of endometrial cancer was described

Full access

7 7 Suppl_6 Suppl_6 NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry Allred D. Craig MD Carlson Robert W. MD Berry Donald A. PhD Burstein Harold J. MD, PhD

Full access

Ingrid A. Mayer

). Genetic Profile of Resistance Genetic alterations are seldom seen in endocrine therapy-sensitive tumors but may be abundant in endocrine Figure 1 Treatment landscape for estrogen receptor–positive metastatic breast cancer. Abbreviations: AI

Full access

Susan M. Domchek, Jill E. Stopfer and Timothy R. Rebbeck

Carlstrom K . Elective ovarian removal and estrogen replacement therapy—effects on sexual life, psychological well-being and androgen status . J Psychosom Obstet Gynaecol 1993 ; 14 : 283 – 293 . 26. Pouilles JM Tremollieres F Bonneu M Ribot C

Full access

Jennifer A. Ligibel and Eric P. Winer

-negative breast cancer who have estrogen-receptor-positive tumors . N Engl J Med 1989 ; 320 : 479 – 484 . 4 Panel NIoHCD . National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1

Full access

Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt and Martin H.N. Tattersall

.org ). Trials that included both estrogen receptor (ER)–positive and ER-negative disease were trials of chemotherapy or targeted therapies, thus we used the NCCN Guidelines regarding the use of these treatment types. The control group of some RCTs tested more